scholarly journals Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials

2019 ◽  
Vol 66 (8) ◽  
Author(s):  
Brianna R. Murphy ◽  
Michael Roth ◽  
E. Anders Kolb ◽  
Todd Alonzo ◽  
Robert Gerbing ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Case Report ◽  
Acute Lymphoblastic Leukemia ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Oncology Group ◽  
Children With Down Syndrome ◽  
Leukemia In Children ◽  
Acute Myeloid

Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia

1991 ◽  
Vol 325 (24) ◽  
pp. 1682-1687 ◽  
Author(s):  
Ching-Hon Pui ◽  
Raul C. Ribeiro ◽  
Michael L. Hancock ◽  
Gaston K. Rivera ◽  
William E. Evans ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Lymphoblastic Leukemia ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Leukemia In Children ◽  
Acute Myeloid

scholarly journals Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421

2008 ◽  
Vol 26 (3) ◽  
pp. 414-420 ◽  
Author(s):  
Maureen M. O'Brien ◽  
Jeffrey W. Taub ◽  
Myron N. Chang ◽  
Gita V. Massey ◽  
Kimo C. Stine ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Disease Free Survival ◽  
Remission Induction ◽  
Oncology Group ◽  
Free Survival ◽  
Children With Down Syndrome ◽  
Age Related ◽  
Acute Myeloid

Purpose To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421. Patients and Methods Children with DS and newly diagnosed AML (n = 57) were prospectively enrolled onto the standard-therapy arm of POG 9421 and were administered five cycles of chemotherapy, which included daunorubicin 135 mg/m2 and mitoxantrone 80 mg/m2. Outcomes and toxicity were evaluated prospectively and were compared with the non-DS–AML cohort (n = 565). A retrospective chart review was performed to identify adverse cardiac events. Results In the DS-AML group, 54 patients (94.7%) entered remission. One experienced induction failure and two died. Of the 54 who entered remission, three relapsed and six died as a result of other causes. The remission induction rate was similar in the non-DS–French-American-British (FAB) M7 (91.7%) and non-DS–non-M7 (89.3%) groups. The 5-year overall survival was significantly better in the DS-AML group (78.6%) than in the non-DS–M7 (36.3%) or the non-DS–non-M7 (51.8%) groups (P < .001). No age-related difference in 5-year, event-free survival was seen between patients younger than 2 years (75.8%) and those aged 2 to 4 years (78.3%). Symptomatic cardiomyopathy developed in 10 patients (17.5%) with DS-AML during or soon after completion of treatment; three died as a result of congestive heart failure. Conclusion The POG 9421 treatment regimen was highly effective in both remission induction and disease-free survival for patients with DS-AML. However, there was a high incidence of cardiomyopathy, which supports current strategies for dose reduction of anthracyclines in this patient population.

Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia

2016 ◽  
Vol 64 (8) ◽  
pp. e26411 ◽  
Author(s):  
Daisuke Tomizawa ◽  
Akifumi Endo ◽  
Michiko Kajiwara ◽  
Hirotoshi Sakaguchi ◽  
Kimikazu Matsumoto ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Down Syndrome ◽  
Acute Lymphoblastic Leukemia ◽  
Myeloid Leukemia ◽  
Lymphoblastic Leukemia ◽  
Previous History ◽  
History Of ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document